search
Back to results

Usefulness of Non-contrast MagnetIc Resonance imAging Versus Non-Contrast Ultrasonography for surveiLlancE of HepatoCellular Carcinoma [MIRACLE-HCC]

Primary Purpose

Compensated Liver Cirrhosis

Status
Unknown status
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Ultrasonography
non-contrast MRI
Sponsored by
Yonsei University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Compensated Liver Cirrhosis

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female subject between 20 and 70 years of age at the time of randomization
  • Has chronic liver disease with compensated liver cirrhosis (Child-Pugh score A), defined as 1) histologically confirmed cirrhosis, or 2) has chronic liver disease and shows the presence of splenomegaly or other typical findings of liver cirrhosis on ultrasonography, computed tomography, or magnetic resonance imaging, or 3) has chronic liver disease and shows the presence of endoscopically-confirmed esophageal or gastric varices
  • Absence of severe cardiovascular, pulmonary, renal or infectious diseases, other than chronic liver disease
  • Absence of a history of malignancy within previous 5 years
  • Can and will comply with the requirements of the protocol (e.g. return for follow-up visits), in the opinion of the investigator
  • Has provided written informed consent

Exclusion Criteria:

  • Greater than 70 years of age
  • Presence of liver cancer or other intrahepatic malignancy
  • Has a history of malignancy within previous 5 years
  • Is pregnant or breast-feeding

Sites / Locations

  • Institute of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Ultrasonography

Non-contrast MRI

Arm Description

Subjects will be regularly screened for HCC by ultrasonography with serum AFP(alpha fetoprotein).

Subjects will be regularly screened for HCC by non-contrast magnetic resonance imaging(MRI) with serum AFP(alpha fetoprotein).

Outcomes

Primary Outcome Measures

Tumor stage of HCC
Comparing tumor stage and resectability rate of HCC between participants undergoing HCC surveillance using ultrasonography and non-contrast MRI.
Resectability rate of HCC
Comparing tumor stage and resectability rate of HCC between participants undergoing HCC surveillance using ultrasonography and non-contrast MRI.

Secondary Outcome Measures

Five-year overall survival
Liver-related mortality
Post-treatment recurrence rate

Full Information

First Posted
July 23, 2015
Last Updated
March 20, 2019
Sponsor
Yonsei University
search

1. Study Identification

Unique Protocol Identification Number
NCT02514434
Brief Title
Usefulness of Non-contrast MagnetIc Resonance imAging Versus Non-Contrast Ultrasonography for surveiLlancE of HepatoCellular Carcinoma [MIRACLE-HCC]
Official Title
Usefulness of Non-contrast MagnetIc Resonance imAging Versus Non-Contrast Ultrasonography for surveiLlancE of HepatoCellular Carcinoma [MIRACLE-HCC]
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Unknown status
Study Start Date
March 30, 2015 (Actual)
Primary Completion Date
December 2022 (Anticipated)
Study Completion Date
December 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yonsei University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The investigators will investigate the usefulness of ultrasonography versus non-contrast magnetic resonance imaging for surveillance of hepatocellular carcinoma through this prospective, randomized trial.
Detailed Description
Hepatocellular carcinoma (HCC) is one of the major complications in patients with chronic liver disease. The prognosis of HCC relies on the extent of disease at the time of diagnosis. Hence to detect cancer at an earlier stage, a regular surveillance test is important for the subjects with a high risk of developing cancer. Current guidelines recommend a regular surveillance using ultrasonography at a 6 month-interval. Ultrasonography is a non-invasive and safe procedure, yet it is limited by the skills of the operator and it is often difficult to differentiate cancer from regenerating nodules especially in atrophied cirrhotic liver. According to a recent meta-analysis, the overall sensitivity and specificity of detecting liver cancer using ultrasonography were both over 90%, however the sensitivity was decreased to 60% in detecting early lesions in which surgery or liver transplantation is indicated. Of note, addition of AFP to ultrasonography also failed to increase the sensitivity in detecting small cancers. Taken together, there is a need to develop a new surveillance test with an improved sensitivity and specificity. Recently, a retrospective study reported that CT or MRI showed a better sensitivity than ultrasonography in detecting early liver cancer. However, performing CT as a surveillance test is limited by frequent exposure to radiation and contrast-dye agent. Although MRI does not have the risk of radiation-exposure, it is limited by the high cost. On the contrast, non-contrast MRI offers a cost that is comparable to US and an absence of exposure to radiation or contrast-dye agent, which suggests non-contrast MRI as a good alternative surveillance tool for early detection of HCC. Therefore, in this prospective, randomized trial, the investigators will investigate the usefulness of ultrasonography versus non-contrast magnetic resonance imaging for surveillance of hepatocellular carcinoma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Compensated Liver Cirrhosis

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
416 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Ultrasonography
Arm Type
Experimental
Arm Description
Subjects will be regularly screened for HCC by ultrasonography with serum AFP(alpha fetoprotein).
Arm Title
Non-contrast MRI
Arm Type
Experimental
Arm Description
Subjects will be regularly screened for HCC by non-contrast magnetic resonance imaging(MRI) with serum AFP(alpha fetoprotein).
Intervention Type
Radiation
Intervention Name(s)
Ultrasonography
Intervention Description
Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
Intervention Type
Radiation
Intervention Name(s)
non-contrast MRI
Intervention Description
Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
Primary Outcome Measure Information:
Title
Tumor stage of HCC
Description
Comparing tumor stage and resectability rate of HCC between participants undergoing HCC surveillance using ultrasonography and non-contrast MRI.
Time Frame
6 months
Title
Resectability rate of HCC
Description
Comparing tumor stage and resectability rate of HCC between participants undergoing HCC surveillance using ultrasonography and non-contrast MRI.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Five-year overall survival
Time Frame
5 years after the study enrollment
Title
Liver-related mortality
Time Frame
5 years after the study enrollment
Title
Post-treatment recurrence rate
Time Frame
5 years after the study enrollment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female subject between 20 and 70 years of age at the time of randomization Has chronic liver disease with compensated liver cirrhosis (Child-Pugh score A), defined as 1) histologically confirmed cirrhosis, or 2) has chronic liver disease and shows the presence of splenomegaly or other typical findings of liver cirrhosis on ultrasonography, computed tomography, or magnetic resonance imaging, or 3) has chronic liver disease and shows the presence of endoscopically-confirmed esophageal or gastric varices Absence of severe cardiovascular, pulmonary, renal or infectious diseases, other than chronic liver disease Absence of a history of malignancy within previous 5 years Can and will comply with the requirements of the protocol (e.g. return for follow-up visits), in the opinion of the investigator Has provided written informed consent Exclusion Criteria: Greater than 70 years of age Presence of liver cancer or other intrahepatic malignancy Has a history of malignancy within previous 5 years Is pregnant or breast-feeding
Facility Information:
Facility Name
Institute of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine
City
Seoul
ZIP/Postal Code
120-752
Country
Korea, Republic of

12. IPD Sharing Statement

Citations:
PubMed Identifier
30249190
Citation
An C, Kim DY, Choi JY, Han KH, Roh YH, Kim MJ. Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial. BMC Cancer. 2018 Sep 24;18(1):915. doi: 10.1186/s12885-018-4827-2.
Results Reference
derived

Learn more about this trial

Usefulness of Non-contrast MagnetIc Resonance imAging Versus Non-Contrast Ultrasonography for surveiLlancE of HepatoCellular Carcinoma [MIRACLE-HCC]

We'll reach out to this number within 24 hrs